[1] Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis, 2013; 17, 375−97. doi:  10.1016/j.cld.2013.05.002
[2] Li Y, Zhang Z, Shi J, et al. Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. Int J Clin Exp Med, 2015; 8, 1205−12.
[3] Zhu B, Liu J, Fu Y, et al. Spatio-temporal epidemiology of viral hepatitis in china (2003-2015): implications for prevention and control policies. Int J Environ Res Public Health, 2018; 15.
[4] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009; 27, 6550−7. doi:  10.1016/j.vaccine.2009.08.048
[5] Zhang W, Ji Z, Fu T, et al. Meta analysis on HBsAg positive rate among general populations age d 1–59 years, 2007–2016, China. Chin J Epidemio, 2017; 38, 1278−84.
[6] Zhang G, Miao N, Zheng H, et al. Incidence by age and region of hepatitis B reported in China from 2005 to 2016. Chin J Vaccine Immu, 2018; 24, 121−6.
[7] Zhang Y, Zhang H, Elizabeth A, et al. Epidemiology of hepatitis B and associated liver diseases in China. Chin Med J, 2012; 27, 243−8.
[8] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015; 386, 1546−55. doi:  10.1016/S0140-6736(15)61412-X
[9] Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med, 2017; 11, 490−501. doi:  10.1007/s11684-017-0598-4
[10] Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis, 2019; 19, 811. doi:  10.1186/s12879-019-4428-y
[11] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. B World Health Organ, 2019; 97, 230−8. doi:  10.2471/BLT.18.219469
[12] Kang L, Zhang J, Zhang Z. Analysis of epidemiological characteristics of hepatitis B and prevention strategy in Wuwei, Gansu province. Bull Dis Contr Pre, 2016; 31, 30−2.
[13] Ji Z, Wang T, Shao Z, et al. A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One, 2014; 9, e97474. doi:  10.1371/journal.pone.0097474
[14] Zheng H, Wang FZ, Zhang GM, et al. The epidemiological characteristics of HBV susceptibility in 1–29 years old young people in China in 2006 and 2014: based on the national sero-survey data analysis. Chin J Epidemiol, 2017; 51, 581−6.
[15] Fan Li, Qixia Wang, Lei Zhang, et al. The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China. Vaccine, 2012; 30, 7118−22. doi:  10.1016/j.vaccine.2012.09.031
[16] Guo M, Luo WW, Zhang DZ. Optimal cessation period of anti-HBV therapy to block mother-to-child transmission. China J Hepatol, 2019; 27, 92−6.
[17] Yan Y, Zhang W, Su H, et al. Research progress and challenges for hepatitis B prevention and treatment in China. Trop Med Int Health, 2019; 19, 916−21.
[18] Nayagam S, Shimakawa Y. Mother to child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J Viral Hepatitis, 2020; 27, 342−9. doi:  10.1111/jvh.13231
[19] Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond), 2018; 50, 95−106. doi:  10.1080/23744235.2017.1384957
[20] Zhang W, Ji Z, Fu T, et al. Meta analysis on HBsAg·positive rate among general populations aged 1-59 years, 2007–2016, China. Chin J Epidemiol, 2017; 38, 1278−84.
[21] Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 2000; 15, Suppl: E25–E30.
[22] Idilman R. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Turk J Gastroenterol, 2017; 28, 412−6. doi:  10.5152/tjg.2017.20817
[23] Hu P, Ren H. Interpretations of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. China J Hepatol, 2017; 25, 415−8.
[24] Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol, 2018; 6, 25−34.
[25] Idilman R. Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines. Turk J Gastroenterol, 2017; 28, 518−21.